Press Announcements > FDA expands approval of Imfinzi to reduce the risk of non-small cell lung cancer progressing

Press Announcements > FDA expands approval of Imfinzi to reduce the risk of non-small cell lung cancer progressing





FDA expands approval of Imfinzi to reduce the risk of non-small cell lung cancer progressing

The U.S. Food and Drug Administration today approved Imfinzi (durvalumab) for the treatment of patients with stage III non-small cell lung cancer (NSCLC) whose tumors are not able to be surgically removed (unresectable) and whose cancer has not progressed after treatment with chemotherapy and radiation (chemoradiation). Continue reading.